Evidence map›Paper›PMID 37521489›Full record

ArticleJournal of experimental pharmacology2023

Efficacy and Anti-Inflammatory Activity of Ashwagandha Sustained-Release Formulation on Depression and Anxiety Induced by Chronic Unpredictable Stress: in vivo and in vitro Studies.

Alluri Venkata KrishnaRaju, Venkateswarlu Somepalli, Shefali Thanawala, Rajat Shah

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. An open-label, single dose, safety and pharmacokinetic study ofDrug metabolism and personalized therapy · 2025
    Article
  15. Article
  16. Antioxidants (Basel, Switzerland) · 2024
    Article
  17. Emerging Vistas for the NutraceuticalPharmaceuticals (Basel, Switzerland) · 2024
    Review
  18. Article
  19. Effect ofInternational journal of applied & basic medical research
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Alluri Venkata KrishnaRajuDepartment of Pharmacology and Clinical Research, Laila Nutraceuticals, Vijayawada, Andhra Pradesh, India.
Venkateswarlu SomepalliDepartment of Research and Development, Laila Nutraceuticals, Vijayawada, Andhra Pradesh, India.
Shefali ThanawalaMedical Affairs, Nutriventia Limited, Mumbai, Maharashtra, India.ORCID 0000-0001-6887-0772
Rajat ShahMedical Affairs, Nutriventia Limited, Mumbai, Maharashtra, India.ORCID 0000-0001-7170-8784
Laila Impex (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Stress is the psychological, physiological, and behavioral response of an individual's body when they perceive a lack of equilibrium between the demands placed upon them and their ability to meet those demands. Adaptogens are herbs that help with stress management, and Ashwagandha is one such safe and effective adaptogen. Objective: We evaluated the anti-neuroinflammatory potential of Ashwagandha sustained-release formulation (AshwaSR) by estimating the in vitro expression of pro-inflammatory cytokines, and its efficacy on anxiety and depression in an in vivo study. Methods: Our in vitro study investigated the anti-inflammatory potential of AshwaSR by estimating the expression of tumour necrosis factor [TNF]-α and interleukin [IL]-1β levels in LPS-induced THP-1 human monocytes, and the antioxidant effects by its potential to inhibit the superoxide [SO] generation in PMA-induced HL-60 human monocytic cells. The in vivo study assessed the efficacy of AshwaSR on chronic unpredictable stress (CUS)-induced comorbid anxiety and depression in Results: AshwaSR inhibited TNF-α, IL-1β and superoxide production in a dose-dependent manner in the in vitro study. The in vivo CUS model induced depression-like and anxiety-like behaviour. Treatments with AshwaSR and escitalopram showed improvement in the EPM and MWM models compared to the CUS-group. Conclusion: In vitro study demonstrated that AshwaSR inhibits expressions of pro-inflammatory cytokines, IL-1β and TNF-α, and superoxide production. Further, the in vivo study confirmed its anxiolytic and stress-relieving effects in the CUS model that confirmed AshwaSR's potential in managing stress and stress-related symptoms.

Indexed as

antidepressantanti-inflammatoryantioxidantanxiolytic stressCUS modelWithania somnifera

Identifiers

PMID37521489
PMCPMC10386834
OpenAlexW4385242007

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.